204 related articles for article (PubMed ID: 16856890)
1. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
Kuhle S; Lau A; Bajzar L; Vegh P; Halton J; Cherrick I; Anderson R; Desai S; McCusker P; Wu J; Abshire T; Mahoney D; Mitchell L
Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
[TBL] [Abstract][Full Text] [Related]
2. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
Matsuzaki A; Suminoe A; Hara T
Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
[TBL] [Abstract][Full Text] [Related]
4. [L-asparaginase, antithrombin III deficiency and thromboses (author's transl)].
Bordigoni P; Briquel E; Olive D
Arch Fr Pediatr; 1981 Nov; 38(9):653-5. PubMed ID: 6949499
[TBL] [Abstract][Full Text] [Related]
5. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
[TBL] [Abstract][Full Text] [Related]
6. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
7. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
8. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
9. [Cerebral sinovenous thrombosis and acquired antithrombin, protein C and S deficiency during chemotherapy in a young man: report of a case].
Munoz VT; Triffet A; Cauchie P; Brohée D
Rev Med Brux; 2008; 29(6):535-9. PubMed ID: 19202708
[TBL] [Abstract][Full Text] [Related]
10. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R
Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854
[TBL] [Abstract][Full Text] [Related]
12. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.
Mitchell LG; Halton JM; Vegh PA; Barr RD; Venneri T; Pai KM; Andrew ME
Am J Pediatr Hematol Oncol; 1994 May; 16(2):120-6. PubMed ID: 8166364
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
[TBL] [Abstract][Full Text] [Related]
14. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes.
Uszyński M; Osińska M; Zekanowska E; Ziółkowska E
Med Sci Monit; 2000; 6(1):108-11. PubMed ID: 11208295
[TBL] [Abstract][Full Text] [Related]
15. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
17. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Leone G; Gugliotta L; Mazzucconi MG; De Stefano V; Belmonte MM; Dragoni F; Specchia G; Centra A; Gamba G; Camera A
Thromb Haemost; 1993 Jan; 69(1):12-5. PubMed ID: 8446931
[TBL] [Abstract][Full Text] [Related]
18. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
19. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia.
Andrew M; Brooker L; Mitchell L
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S24-36; discussion S59-64. PubMed ID: 8186353
[TBL] [Abstract][Full Text] [Related]
20. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
